Natriuretic peptides play an important role in water and salt homeostasis and in the regulation of the cardiovascular system. In recent years, exogenous administration of natriuretic peptides has primarily been used to improve our understanding of the role of natriuretic peptides. Also, it became evident that natriuretic peptides may be used therapeutically. Because of their peptide character, they cannot be administered orally and, therefore, may be used for short-term intravenous therapy only. In recent years, inhibitors of neutral endopeptidase, which degrades natriuretic peptides to inactive metabolites, have been investigated. This review focuses on the potential benefits of increasing natriuretic peptide levels, either through exogenous administration or inhibiting the degradation of endogenous natriuretic peptides.
Rationale for the therapeutic increase in natriuretic
development of arteriosclerosis, hypertension and progrespeptides levels sion of congestive heart failure (CHF) [7] [8] [9] .
Natriuretic peptides are importantly involved in water 1.1. Natriuretic peptides in various cardiovascular and sodium balance and cardiovascular homeostasis (Fig.  diseases  1) . In response to an increase in filling pressures and stretch of the atrial and ventricular walls, atrial natriuretic
The pivotal role of natriuretic peptides in the early peptide (ANP) and brain or B-type natriuretic peptide development of CHF has been demonstrated in various (BNP) are released into the bloodstream [1, 2] . In addition, animal studies. Prevention of the early rise of ANP in several neurohormones such as endothelin-1 (ET-1), arpacing-induced CHF by surgical removal of the atrial ginine vasopressin (AVP), and catecholamines stimulate auricles may result in hemodynamic deterioration and in the secretion of natriuretic peptides [3, 4] . This leads significant activation of the renin-angiotensin system [10] . primarily to a reduction in preload by increasing water and
In contrast to ANP, BNP is not or only minimally elevated sodium excretion, but also by shifting plasma from the in acute pacing-induced CHF [11] . Administration of BNP intravascular to the extravascular space [5] . The effects of resulted in haemodynamic improvement and prevention of ANP and BNP are mediated by the transmembrane water and sodium retention [11] , a finding we recently guanylyl-cyclase receptor type A, which promotes intracelcould confirm (unpublished data). However, further inlular cGMP formation. Thus, they cause arterial and crease in already elevated serum ANP levels in this setting venous vasodilation [6] . Additional important properties was without effect (unpublished data, Fig. 2 ). In patients include the ability to inhibit the activity of various suffering from large myocardial infarction the rise in neurohumoral systems, involved in the pathogenesis and BNP-levels results in left ventricular systolic dysfunction, which is seen as a compensatory mechanism to prevent further deterioration [12] . In chronic CHF, natriuretic models. Transgenic mice overexpressing ANP or BNP were shown to have lower blood pressure than control animals [16, 17] . Disruption of the pro-ANP gene in mice elevated blood pressure, particularly in the presence of salt-rich diet [18] . Salt-resistant hypertension was observed in mice lacking the guanylyl cyclase type A receptor [19] . Further, ANP may play a role in counteracting excess of mineralocorticoids [20].
Effects of natriuretic peptides on other neurohormones and mitogenesis
In addition to the well-described inhibitory effect on renin release [21] , natriuretic peptides may also counteract other vasoconstrictor neurohumoral systems. Among others, natriuretic peptides may inhibit ET-1 secretion in Fig. 1 . Effects of natriuretic peptides released from the heart as a result vitro [8] . Moreover, there is general agreement that ANP of increased cardiac wall stretch (increased venous return) or various neurohormones. Both peripheral and central effects lead to reduction of inhibits sympathetic activity [9, 22, 23] , despite some conthe initial promoters. ? denotes effects or mechanisms not yet completely tradictory findings [24] . Effects of BNP in this context are elucidated. ANP, atrial natriuretic peptide; AVP, arginine vasopressin; less well known. We have recently found inhibition of BNP, brain natriuretic peptide; ET-1, endothelin-1; SNS, sympathetic systemic and regional sympathetic activity by exogenous nervous system. BNP in both healthy controls and CHF patients [25] , pointing to a potential role of natriuretic peptides in the peptides may contribute to maintenance of cardiac function regulation of the sympathetic nervous system. in early, asymptomatic stages of disease. At a later stage, Moreover, natriuretic peptides have antimitogenic activihowever, progression of CHF may be related to loss of ty. ANP and C-type natriuretic peptide (CNP) have been efficacy of natriuretic peptides [13] .
shown to inhibit mitogenesis in cultured vascular smooth Natriuretic peptides may also play a role in arterial muscle cells and in balloon injured carotid arteries [26, 27] . hypertension. Polymorphism of the ANP gene was found These effects seem to be cGMP-mediated, implying that in some patients with essential hypertension [14] . Morenatriuretic peptides may modulate growth in the vessel over, a lower ratio of the guanylyl-cyclase type A receptor wall and possess inhibitory properties on the development to the clearance receptor was found in obesity-related of arteriosclerosis [28] . ANP further inhibits growth of hypertension [15] . Other evidence derives from animal cardiac fibroblasts in vitro, independently of the underlying mechanism of stimulated proliferation [29, 30] . Therefore, natriuretic peptides may favourably affect remodelling by reducing the myocardial proliferative response to injury.
Effects of systemic and local administration of natriuretic peptides
The hemodynamic effects of natriuretic peptides have been widely investigated in both health and cardiovascular disease. Whereas reduction in cardiac filling pressures has been almost uniformly reported, arterial vasodilatation as a response to natriuretic peptides is less consistent. In theory, one would expect reduction in systemic vascular resistance. Some studies showed an increase in cardiac output despite significant reduction in filling pressures [31] [32] [33] . Others have reported no effect on or even an increase in pmol / kg per min) in a crossover comparison in acute pacing-induced heart failure (AHF) in eight dogs (mean6S.E.M.). Tachycardic pacing systemic vascular resistance [34] [35] [36] . The latter finding was applied for 1 h to increase pulmonary wedge pressure (PCWP) to 15 might be explained by a counterregulatory activation of mmHg before ANP and BNP was given for 30 min each in random order.
baroreceptors with high doses of natriuretic peptides [28] , Between infusions, there was a washout period of 30 min. *All differdespite their inhibitory effect on the sympathetic nervous ences between ANP and BNP P,0.01 (Wilcoxon Exact Test). CO, system and the lowering of the activation threshold of cardiac output; SVR, systemic vascular resistance; RAP, right atrial pressure.
vagal afferents [37] .
The arterial response to exogenous natriuretic peptides 2.2. Administration of natriuretic peptides in coronary may vary regionally. Natriuretic peptides cause vasodilatartery disease ation in renal afferent arterioles but vasoconstriction in efferent arterioles [38] , increasing the glomerular hydroNatriuretic peptides have effects that are of potential static pressure, and thereby enhancing glomerular filtration benefit in coronary artery disease. Thus, infusion of ANP rate. In healthy conscious dogs, natriuretic peptides have reduced the extent and severity of myocardial perfusion been shown to cause mesenteric vasoconstriction, but defects and prevented ST-segment depression during exerdifferent responses have been observed in other vascular cise [42] . Both ANP and BNP infused into the left main beds in the same animals. Interestingly, the vascular coronary artery increase coronary sinus blood flow and response was independent of the autonomic nervous decrease coronary vascular resistance [54, 55] . Natriuretic system [39, 40] . Thus, natriuretic peptides seem to be peptides may reduce chest pain and ECG changes in involved in the distribution of regional blood flow. Alpatients with vasospastic angina [56] . It has been sugthough the underlying mechanism for the vasoconstrictive gested that ANP improves myocardial perfusion to areas of effect of natriuretic peptides is still unexplained, it may be ischaemia by acting on collateral vessels [57] . Pacinghypothesised that the arterial response to natriuretic pepinduced myocardial ischaemia has been attenuated in tides is not uniform and depends on the underlying patients with coronary stenosis with but not in patients conditions. So far, systemic vasodilatation has primarily without collaterals [58] . Natriuretic peptides may therefore been observed in patients with manifest cardiovascular or contribute to the local homeostatic regulation during renal disorders [31] [32] [33] 36] .
conditions of myocardial ischaemia, similarly to the local Because of the prevailing beneficial effects, there was distribution of blood discussed earlier [39] . early interest in the therapeutic use of ANP in humans
There may be additional effects that are beneficial in the [41] . Other atrial natriuretic peptides, such as urodilatin acute coronary syndrome. Neutrophils incubated in either (i.e. proANP(95-126)) and vessel dilator (i.e. proANP (31- ANP or BNP showed less adhesion and elastase release, 67)), and BNP received attention. Administration of natand reduced detachment of endothelial cells [59] . Neutroriuretic peptides has been investigated in patients with phils are believed to contribute to endothelial cell damage various cardiovascular conditions such as arterial hypertenin ischemic and reperfusion injury. They contain neutral sion [21] , myocardial infarction, coronary artery disease endopeptidase, which is significantly increased in acute [42, 43] , and CHF [44] . Moreover, therapeutic use of myocardial infarction [60] . Thus, deficient inhibition of natriuretic peptides was considered in other conditions, neutrophils by natriuretic peptides in acute coronary such as renal insufficiency [45, 46] , liver cirrhosis [47, 48] , syndrome may play an essential pathophysiological role. bronchial obstruction [49, 50] , and in the immediate postThis may be seen in line with the relationship of elevated operative period after cardiac surgery [51] .
white blood cell counts to reduced myocardial perfusion and high incidence of new CHF in acute myocardial infarction [61] . Infusion of natriuretic peptides may there-2.1. Administration of natriuretic peptides in arterial fore prove to be useful in patients with acute coronary hypertension syndromes.
In arterial hypertension, ANP has been shown to sig-2.3. Administration of natriuretic peptides in congestive nificantly reduce blood pressure in a dose-dependent heart failure manner [21, 36] . In addition to increasing sodium and water excretion, which may be enhanced compared to healthy Several studies investigated the effects of natriuretic controls [52] , natriuretic peptides may significantly reduce peptides on haemodynamics, renal function, and other the activity of the renin-angiotensin-aldosterone system circulating neurohormones in CHF. The majority of the [21] . Moreover, infusion of BNP was found to improve human studies were conducted in patients with advanced diastolic function of the left ventricle in patients with CHF. Initial results were promising as they showed a isolated diastolic CHF due to hypertensive heart disease significant reduction in filling pressures and systemic [53] . These effects are desirable and may be more favourvascular resistance with an increase in cardiac output [62] . able than those of other antihypertensive drugs, some of Sodium and water excretion were increased and both which may stimulate vasoconstrictor neurohumoral syscirculating noradrenaline and aldosterone decreased comtems. However, lack of an oral form imposes limitations. pared to placebo [44] . The expectations were slowed down Acute decompensation of pure diastolic CHF may be an when it became evident that the efficacy of natriuretic exception to this notion [53] . Nevertheless, these studies peptides may be lost over time as CHF progresses [63, 64] . expand the current pathophysiological understanding of This phenomenon seems to correlate with the transition arterial hypertension and set the stage for the use of drugs, from asymptomatic to overt CHF [13] . In the human which aim to increase the endogenous levels of natriuretic forearm model, both intra-arterial ANP and BNP caused peptides (i.e. neutral endopeptidase inhibitors, see below).
less vasodilatation and local production of cGMP in patients with CHF than in healthy volunteers [63] . The production of cGMP in relationship to the extraction of ANP across the lung [65] and the leg [64] was significantly reduced in advanced compared to early CHF. One of the underlying factors for this observation may be downregulation of the guanylyl-cyclase type A receptor although this
has not yet been specifically investigated in CHF. Downregulation of this receptor was found in patients with chronically elevated levels of natriuretic peptides in chronic but not in paroxysmal atrial fibrillation [66] . However, natriuretic peptides in CHF were not found in all studies [67] . Moreover, hyporesponsiveness may differ between various types of natriuretic peptides [68] . A recent study showed that vessel dilator strongly enhanced sodium Although not based on scientific grounds, it was postulated that hyporesponsiveness is also less pronounced for BNP than for ANP [70] . Intravenous administration of respectively, P50.03). After 6 h, dyspnoea was improved BNP caused a dose-dependent reduction in filling pressures in 56 and 50% of the patients receiving low and high dose and peripheral vascular resistance and an increase in nesiritide, respectively, but in only 12% of the patients cardiac output in patients with acutely decompensated receiving placebo (P,0.001). A similar reduction in CHF [70] . Most recently, the beneficial hemodynamic fatigue (32 and 38%, respectively, vs. 5%, P,0.001) and effects of BNP (nesiritide, i.e. recombinant human BNP) in improvement in clinical status (Fig. 4) were observed. In a symptomatic CHF were confirmed in two large studies second comparative arm, the two doses of nesiritide (0.015 [31, 32] .
mg / kg per min, n5103; 0.03 mg / kg per min, n5100) The first of these studies investigated the hemodynamic were compared with standard therapy (n5102; most effects of three different doses of nesiritide (0.015, 0.03, commonly dobutamine) for up to 7 days to detect changes and 0.06 mg / kg per min) over 24 h compared to placebo in in symptoms and to evaluate safety. There were similar 103 patients with decompensated CHF [31] . Patients had a improvements in symptoms in all three treatment groups. pulmonary capillary wedge pressure $18 mmHg and a Although the patients lost similar amounts of weight, 2 cardiac index #2.7 l / min per m . Nesiritide had beneficial intravenous diuretics were less often needed in patients dose-dependent hemodynamic effects. The drug was genassigned to nesiritide (84 and 75%, respectively) than in erally well tolerated, but hypotension occurred more often patients under standard treatment (96%, P,0.001). The with high doses of BNP (P50.027 trend test). Unexpectedly, there were no significant effects on sodium or water excretion. This may be in contrast to the renal effects observed with vessel dilator [69] , although no direct comparison of these two agents in CHF has been published. Hemodynamic peak effects of nesiritide were seen 3 h after the start of infusion and persisted to the end of the infusion (24 h). No rebound effect was observed after cessation of the infusion.
The largest trial investigating the therapeutic use of BNP in CHF has been published most recently [32] . In a first arm with 127 patients, efficacy of 0.015 and 0.03 mg / kg per min of nesiritide over 6 h was compared to placebo. The results showed beneficial hemodynamic changes (Fig.   Fig. 4 . Effects on overall symptoms of two doses of nesiritide (human 3), increased urine production (mean urine output over 6 h: BNP, mg / kg per min) versus placebo in acute decompensated heart failure placebo vs. low dose vs. high dose nesiritide 380, 560 and (n5127). Symptoms were assessed on a five-category scale. Comparison 659 ml, respectively, P50.004), and reduction in plasma among the three groups, P,0.001 by non-parametric ANOVA. Adapted aldosterone concentration (117, 269, and 244 pmol / l, from Colucci et al. [32] . most common side effect of nesiritide was dose-related, 2.5. Administration of natriuretic peptides in other mostly asymptomatic hypotension (12 and 24%, respecconditions tively, vs. 7%, P,0.01). Bradycardia was more common in the nesiritide groups (4 and 5%, respectively, vs. 0%, Similarly controversial conclusions were drawn in pa-P,0.05) and nonsustained ventricular tachycardia was tients with liver cirrhosis. Both a blunted and a preserved noted less in the high dose nesiritide group (1%) than in response to natriuretic peptides have been found in adthe other two groups (low dose nesiritide 10%, standard vanced liver disease [47, 48, 80, 81] . In theory, the renal therapy 8%, P,0.05).
effects of natriuretic peptides, if preserved, may help to These trials underline the potential benefit of nesiritide reduce the pressure in the portal vein. Furthermore, in decompensated CHF. Standard therapy in this setting although natriuretic peptides do not seem to have direct still requires intravenous diuretics, dobutamine, milrinone, effects on hepatic vascular conductance [40] , the reduction nitroglycerin, and sodium nitroprusside. All these therapies in mesenteric blood flow may further contribute to a have significant drawbacks, including arrhythmias reduced portal venous pressure [39] . This is in line with (dobutamine, milrinone [71] , potentially augmented by other experimental data, which show that natriuretic pepelectrolyte disturbances due to diuretics [72] ), development tides may reduce portal venous pressure despite loss of of tolerance (nitroglycerin [73] ), toxic effects (sodium renal effects in cirrhotic rats [81] . It remains to be seen nitroprusside), and stimulation of vasoconstrictor neurowhether this is of therapeutic significance in humans with humoral systems (pure vasodilators). Hypotension as the portal hypertension. most common side effect of nesiritide might be overcome
In patients with bronchoconstriction, local (i.e. inhaled) by careful uptitration, which so far has not been tested.
and systemic application of natriuretic peptides consistently caused bronchodilation [49, 50, 82] . The combined use of a locally applied substance increasing cAMP (b2-stimula-2.4. Administration of natriuretic peptides in acute renal tion) with systemic urodilatin, which increases cGMP, was failure significantly more effective than either therapy alone [50] . In addition, ANP may act as a bronchoprotective agent In experimental and small human studies, atrial natafter allergic reactions [83] . Currently, there are insuffiriuretic peptides showed beneficial effects in acute renal cient data available about the long-term effects of natfailure [74, 75] . ANP was also investigated in an openriuretic peptides in such patients with bronchoconstriction. label, clinical study in 53 patients with acute tubular Seemingly, rather high doses are needed to obtain signifinecrosis, transiently increasing creatinine clearance during cant effects with locally applied ANP [84] . Thus, costinfusion and decreasing the need for dialysis [45] . In effectiveness may prevent natriuretic peptides from being contrast, a randomised double-blinded trial failed to show used as a therapeutic agent for bronchoconstriction. anatritide, a synthetic 25-amino-acid form of ANP, to Natriuretic peptides have also been investigated during ameliorate dialysis-free survival in 504 critically ill pacardiac surgery [51, 85, 86] . A low ANP dose had favourtients with acute tubular necrosis [46] . Nevertheless, in a able effects given during and for the first 24 h after predefined subgroup of patients with oliguria (i.e. ,400 ml coronary bypass grafting, improving hemodynamics and urine / day), a 24-h infusion of anatritide improved dialysisrespiratory index and reducing neurohumoral stimulation, free survival to 27% compared to 8% in the placebo use of diuretics, and pleural effusions [51] . Similarly, ANP treated group (P50.008). However, anatritide was detriimproved hemodynamics and augmented urinary excretion mental in the non-oliguric patient population (48 vs. 59% given on the first postoperative day after open-heart dialysis-free survival, P50.03). Whether underlying surgery [85] . The same was found in patients undergoing pathophysiological conditions and / or the type of natFontan operation [86] . Therefore, administration of natriuretic peptide may be important in this regard needs to be riuretic peptides during the perioperative period may be tested. A recent study in rats with established ischemic beneficial and may deserve further investigation. non-oliguric acute renal failure found marked improvement in survival by vessel dilator [76] . In contrast, urodilatin did not reduce the incidence of renal replacement therapy in 3. Increasing endogenous levels of natriuretic critically ill patients suffering form oliguric acute renal peptides failure [77] . Additionally, urodilatin did not improve renal function in patients with acute renal failure after major Long-term increase in natriuretic peptides may be a abdominal surgery [78] , but was effective in acute renal desirable therapeutic target. So far, the only means to failure after cardiac surgery [74, 79] . So far, the results of achieve this goal is to reduce the degradation of natriuretic studies with natriuretic peptides in acute renal failure are peptides by neutral endopeptidase inhibition [87] . Selective controversial and at this time, there is no clear evidence to neutral endopeptidase inhibition increases the levels of support a therapeutic role in this setting.
natriuretic peptides, resulting ultimately in increased excre-tion of sodium, water, ANP, and cGMP without altering pressure in 71% of patients with mild hypertension [103] . urinary potassium excretion [88] . However, neutral endoThe high response rate may relate to the fact that omapatpeptidase inhibition has demonstrated only a limited ability rilat may be effective independently of the renin levels. to lower systemic blood pressure [89] , which may be Thus in patients with salt-sensitive low renin hypertension, related to vasoconstrictive properties of selective neutral as often observed in black individuals, ACE inhibitors endopeptidase inhibition [90] . In addition to the vasoconusually are not as effective as in patients with normal or strictive potential of natriuretic peptides [39] , other mechahigh renin levels [104] . In these patients, inhibition of nisms may be accountable for these findings. Neutral neutral endopeptidase may be important as it enhances the endopeptidase is involved not only in degradation of ET-1 levels of natriuretic peptides and lowers plasma volume. [91] but possibly also in its formation [92] . Thus, selective
Although direct comparisons of omapatrilat with other inhibition of neutral endopeptidase might cause both an blood pressure lowering agents are scarce, omapatrilat increase and decrease in endothelin-1. Increased levels of seems to be one of the most efficacious antihypertensive circulating ET-1 could be demonstrated after administradrugs yet known. tion of candoxatril, a selective neutral endopeptidase There are effects of omapatrilat beyond pure blood inhibitor [89] . Similarly, locally applied candoxatrilat pressure lowering. As elevated neurohumoral stimulation caused vasoconstriction which could be reverted by a is increasingly recognised as an important factor in the selective ET receptor antagonist [93] . Importantly, neutral pathophysiology of CHF [105] , this is also found to be true A endopeptidase is also involved in the degradation of in hypertension [106, 107] . Similarly, the recently pubangiotensin-II (Ang II). Consequently, inhibition of neutral lished HOPE study could show that ACE inhibition endopeptidase leads to increased levels of Ang II [94] .
favourably affects prognosis in patients with arterioscleroApart from bearing potential vasoconstrictive effects, Ang sis independently of the magnitude of blood pressure II may antagonise the effects of the natriuretic peptides. It lowering [108] . Because of the additional properties of down-regulates guanylyl cyclase receptors and up-regomapatrilat, one might speculate that long-term effects of ulates cGMP phosphodiesterases, both of which attenuate this new therapeutic tool might prove even better in the generation of cGMP [30, 95] . Therefore, simultaneous improving prognosis in this patient population. inhibition of both neutral endopeptidase and angiotensin converting enzyme (ACE) may be synergistic and a 3.2. Vasopeptidase inhibition in congestive heart failure promising approach to modulate neurohumoral stimulation in cardiovascular diseases [88] . In line with this concept, Despite significant advances in the medical therapy of simultaneous inhibition of both neutral endopeptidase and CHF in recent years, prognosis of these patients remains ACE in animal experiments exhibited hemodynamic and poor [109, 110] . On the one hand, vasoconstrictor neurorenal effects that were more than additive compared to humoral systems may overcome the endogenous counterthose caused by inhibition of either one of these enzymes regulatory mechanisms, resulting in progression of CHF alone [96] [97] [98] . Recently, omapatrilat, a vasopeptidase [111] . On the other hand, sodium and water retention cause inhibitor that inhibits both neutral endopeptidase and ACE, significant problems in these patients. This may, in turn, has been developed [99] . Omapatrilat shows equipotent, result in deterioration of CHF and hospitalisation [112] . highly selective competitive inhibition of both enzymes, Standard loop-diuretics increase water and salt excretion, although the rate constant (K ) is slightly higher for neutral but also increase potassium excretion leading to an elei endopeptidase (8.961.0 nmol / l) than for ACE (6.060.4 vated risk of hypokalemia-induced arrhythmias [113] . In nmol / l). Therefore, omapatrilat acts primarily as an ACE addition, they also stimulate vasoconstrictor neurohumoral inhibitor in low dosages while it inhibits both enzymes in systems, in particular the renin-angiotensin system. In higher dosages.
contrast, vasopeptidase inhibitors may overcome this problem, by increasing water and sodium excretion and reduc-3.1. Vasopeptidase inhibition in hypertension ing preload without affecting potassium excretion and without stimulating vasoconstrictor neurohumoral systems Preclinical studies showed the potential advantages of [88] . In dogs, omapatrilat has been shown to improve omapatrilat over pure ACE-inhibition in various models of cardiac function in pacing-induced CHF [114] . Furtherhypertension [100, 101] . Thus, omapatrilat lowered elemore, omapatrilat was not only able to improve left vated blood pressure in conscious rats with high, medium, ventricular geometry compared to captopril, but also to or low renin hypertension [100] . In comparison with a improve survival in cardiomyopathic hamsters [98] . These calcium antagonist and an ACE inhibitor, omapatrilat was studies might indicate the superiority of a combined superior in lowering blood pressure. More recently, the inhibition of neutral endopeptidase and ACE compared to efficacy of omapatrilat was reported in hypertensive pa-ACE inhibition alone. tients, where it lowered blood pressure in a dose-dependent Most recently, the IMPRESS trial randomly compared manner [102] . Furthermore, omapatrilat normalised blood omapatrilat (target dose 40 mg daily) with the ACE inhibitor lisinopril (target dose 20 mg) in 573 CHF patients (ejection fraction#40%) over 24 weeks [115] . Although there was no difference between the two treatment groups with respect to the primary endpoint of maximal exercise capacity, there were fewer cardiovascular serious adverse events in the omapatrilat group than in the lisinopril group (7 vs. 12%, P50.04). Furthermore, there was a trend towards less combined endpoints of death and admission to hospital for worsening CHF and a significant reduction in the combined endpoint of death, admission to a hospital or discontinuation of study treatment due to worsening CHF (Fig. 5) . There was also a trend towards improvements in symptoms of CHF, particularly in highly symptomatic patients. Although these data are very promising, one has to be cautious not to over-interpret them, as this study was not powered to investigate the prognostic effects of omapatrilat versus isolated ACE inhibition. Underpowered studies may lead to false positive results as recently shown in the ELITE-1 trial [116] , which could not be confirmed in the properly powered ELITE-II study [117] .
Another study compared different dosages of omapatrilat in patients with CHF, most of them previously treated with either an ACE inhibitor and / or angiotensin-II receptor antagonists [118] . There was a dose-dependent improvement in the clinical CHF status with good overall tolerability of the drug. Moreover, clinical and hemodynamic improvements were dose-dependent and significantly different between the three groups for arterial There was also a significant enhancement in water and in humans with left ventricular ejection fraction #40%. Comparisons among the three groups P,0.01 by one-way ANOVA. Adapted from sodium excretion and a reduction in blood volume. All
McClean et al. [118] .
these changes were dose-dependent. The increased cGMP production as measured by urinary cGMP seemed to be an important mechanism of the additional effects of omapatrilat. Nevertheless, large-scale controlled clinical trials have to prove the superiority of this concept over isolated 3.3. Tolerability of vasopeptidase inhibition ACE inhibition (6diuretics) before omapatrilat may be recommended for the treatment of CHF.
Despite the promising data in both arterial hypertension and CHF, there are important caveats. In both studies [115, 118] , only patients with prior ACE inhibitor treatment were included, with few exceptions. Therefore, it is not surprising that few ACE-inhibition specific adverse effects were reported. With this in mind, one has to be cautious when comparing the tolerability of omapatrilat with ACE inhibitors [119] . Though rare, a potentially fatal adverse effect of ACE inhibition is angioedema. The widespread use of ACE inhibitors may lead to a significant number of deaths due to angioedema. Inhibition of neutral endopeptidase not only increases the levels of endogenous natriuretic peptides but also of other vasodilators such as a prostacyclin, adrenomedullin and, more important in this context, bradykinin [97] . Accumulation of bradykinin is Hosp. denotes hospitalization. Adapted from Rouleau et al. [115] .
that angioedema is more common with vasopeptidase in 0.34% of the more than 4000 patients treated with those of A-type natriuretic peptide in normal subjects and patients ramipril in the HOPE study [108] . In data submitted for the with heart failure. tion of angioedema [121] . Therefore, the risk-benefit ratio the short-to medium-term mortality is relatively low. 
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